{"id":"NCT03355820","sponsor":"GlaxoSmithKline","briefTitle":"A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study","officialTitle":"Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-28","primaryCompletion":"2018-06-29","completion":"2018-06-29","firstPosted":"2017-11-28","resultsPosted":"2019-06-10","lastUpdate":"2020-11-19"},"enrollment":228,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Cervical Intraepithelial Neoplasia"],"interventions":[{"type":"PROCEDURE","name":"Blood sampling for antibody determination","otherNames":[]}],"arms":[{"label":"HPV Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study. No new subjects will be enrolled in this extension study.","primaryOutcome":{"measure":"Number of Seropositive Subjects for Anti-HPV-16 Antibodies at Day 1 in HPV-093 (NCT03355820) Study","timeFrame":"At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study)","effectByArm":[{"arm":"HPV Group","deltaMin":223,"sd":null}],"pValues":[]},"eligibility":{"minAge":"17 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["32780946"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":227},"commonTop":[]}}